Leerink Partners Rates ABIVAX Société Anonyme (ABVX) buy

Analyst Thomas Smith maintains a buy rating on ABIVAX Société Anonyme with a price target of $148, a 10.09% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 12:01 PM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated ABIVAX Société Anonyme ($ABVX) "buy" with a $148 price target on June 30, 2026.

Since the rating, $ABVX is up 6.7% after 1 week, down 6.7% after 1 month and down 33.9% to date (from the $133.26 close on Jun 30, 2026).

ABVX ABIVAX Société Anonyme

$88.13 -34.12% year to date

Daily close · Oct 16, 2026

Key Points

Leerink Partners analyst Thomas Smith reiterated a buy rating on ABIVAX Société Anonyme NasdaqGM:ABVX with a $148 price target on June 30, 2026.
Leerink Partners's $148 price target implies 10.09% upside from ABIVAX Société Anonyme's ($ABVX) current $134.44 share price.
The biotechnology company trades near $134.44 per share, positioned between its 52-week low of $69.81 and its 52-week high of $148.83.
Wall Street sentiment remains strong overall, backed by a consensus recommendation of strong buy and a mean price target of $163.58 across 12 analyst opinions.

Get $ABVX trade alerts by text

We text you when insiders, Congress or big funds trade $ABVX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ABIVAX Société Anonyme alert may contain errors. Disclosures

Leerink Partners Reaffirms View on ABIVAX

Leerink Partners analyst Thomas Smith maintained his positive stance on ABIVAX Société Anonyme NasdaqGM:ABVX on June 30, 2026, keeping a buy rating and setting a price target of $148. The update continues a steady stream of evaluations from major financial institutions tracking the clinical-stage biotech firm.

Analyst rating track record

Leerink Partners vs. the S&P 500

YTD return +44.67% hypothetical

All-time return +44.67% S&P 500 +8.12%

vs. S&P 500 +36.55% ahead of the index

Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.

Stock Price and Market Standing

Shares changed hands at $134.44 recently. The equity has traversed a wide range over the past year, finding a floor at $69.81 and climbing as high as $148.83. Market participants continue to watch the valuation closely as clinical programs progress toward upcoming milestones.

12-month forecast

$ABVX price target

ABIVAX Société Anonyme daily closes and this analyst's $148 target. Not advice.

Broad Analyst Coverage and Price Targets

Wall Street firms have regularly updated their outlooks on the Paris-based drug developer. On September 22, 2026, Truist Securities kept a buy rating while adjusting its target to $151 from $155, and Wedbush maintained a neutral rating with its target moved to $118 from $140. Barclays kept an overweight rating at $148 on the same day. Earlier in the month, Goldman Sachs started coverage with a buy rating and a $155 target on September 10, 2026, while BTIG reiterated a buy rating with a $175 target on September 5, 2026. Looking back at earlier summer updates, Piper Sandler maintained an overweight rating with a target of $175 on July 9, 2026, Truist Securities kept a buy rating with a $155 target on July 2, 2026, and Citizens reiterated a market outperform rating with a $187 target on July 1, 2026. Across 12 analyst opinions, the overall sentiment is a strong buy with a mean price target of $163.58, with individual targets ranging from a low of $142 to a high of $181.

What ABIVAX Does

ABIVAX Société Anonyme is a clinical-stage biotechnology company centered on developing treatments that regulate the body's immune response for chronic inflammatory conditions. Its primary drug candidate, obefazimod, is undergoing late-stage clinical evaluation for moderately to severely active ulcerative colitis, alongside mid-stage studies for Crohn's disease. Founded in 2013, the enterprise operates out of Paris, France, employing a lean team dedicated to inflammatory disease therapeutics.

What to Watch at ABIVAX Société Anonyme

The ongoing updates from firms like Leerink Partners reflect continued interest in the progression of obefazimod through clinical trials. Investors will look toward future pipeline announcements and the next scheduled financial report expected on March 22, 2027, for further indicators of operational progress.